Metformin XR + Saxagliptin + Saxagliptin-Metformin XR
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Polycystic Ovary Syndrome
Conditions
Polycystic Ovary Syndrome, Disorder of Glucose Regulation
Trial Timeline
Mar 1, 2014 → Oct 1, 2016
NCT ID
NCT02022007About Metformin XR + Saxagliptin + Saxagliptin-Metformin XR
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR is a phase 3 stage product being developed by AstraZeneca for Polycystic Ovary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02022007. Target conditions include Polycystic Ovary Syndrome, Disorder of Glucose Regulation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02022007 | Phase 3 | Completed |
Competing Products
20 competing products in Polycystic Ovary Syndrome